Clinical significance of Treg cell frequency in acute myeloid leukemia

International Journal of Hematology

Volumn 98, Issue 5, 2013, Pages 558-562

  Yang, Wenjuan ^a   Xu, Yunxiao ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Acute myeloid leukemia (AML); Regulatory T cell

Indexed keywords

CYTARABINE; DAUNORUBICIN; HOMOHARRINGTONINE; INTERLEUKIN 7 RECEPTOR; ANTINEOPLASTIC AGENT; CD5 ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 7 RECEPTOR ALPHA;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CD4+ CD25+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOGENETICS; CYTOLOGY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOPHENOTYPING; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PERIPHERAL BLOOD MONONUCLEAR CELL; REGULATORY T LYMPHOCYTE; TREATMENT OUTCOME; YOUNG ADULT; CANCER STAGING; IMMUNOLOGY; LEUKEMIA, MYELOID, ACUTE; METABOLISM; MORTALITY; PHENOTYPE; PROGNOSIS;

ADULT; AGED; ANTIGENS, CD5; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; IMMUNOPHENOTYPING; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; INTERLEUKIN-7 RECEPTOR ALPHA SUBUNIT; LEUKEMIA, MYELOID, ACUTE; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; NEOPLASM STAGING; PHENOTYPE; PROGNOSIS; T-LYMPHOCYTES, REGULATORY; YOUNG ADULT;

MLCS; MLOWN;

EID: 84892912967     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-013-1436-3     Document Type: Article

References (22)

1. Smits EL, Berneman ZN, Van Tendeloo VF. Immunotherapy of acute myeloid leukemia: current approaches. Oncologist. 2009;14:240-52.
2. Kanakry CG, Hess AD, Gocke CD, Thoburn C, Kos F, Meyer C, et al. Early lymphocyte recovery after intensive timed sequential chemotherapy for acute myelogenous leukemia: peripheral oligo clonal expansion of regulatory T cells. Blood. 2011;117:608-17.
3. Ustun C, Miller JS, Munn DH, Weisdorf DJ, Blazar BR. Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation? Blood. 2011;118:5084-95.
4. Szczepanski MJ, Szajnik M, Czystowska M, Mandapathil M, Strauss L, Welsh A, et al. Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia. Clin Cancer Res. 2009;15:3325-32.
5. Pandolfi F, Cianci R, Lolli S, Dunn IS, Newton EE, Haggerty TJ, et al. Strategies to overcome obstacles to successful immunotherapy of melanoma. Int J Immunopathol Pharmacol. 2008;21: 493-500.
6. Robak T, Wrzesieon-Kuos A. The search for optimal treatment in relapsed and refractory acute myeloid leukemia. Leuk Lymphoma. 2002;43:281-91.
7. Mato AR, Morgans A, Luger SM. Novel strategies for relapsed and refractory acute myeloid leukemia. Curr Opin Hematol. 2008;15:108-14.
8. Kelley TW, Parker CJ. CD4 CD25 Foxp3 regulatory T cells and hematologic malignancies. Front Biosci (Schol Ed). 2010;2:980-92.
9. Wang X, Zheng J, Liu J, Yao J, He Y, Li X, et al. Increased population of CD4 CD25(high), regulatory T cells with their higher apoptotic and proliferating status in peripheral blood of acute myeloid leukemia patients. Eur J Haematol. 2005;75: 468-76.
10. Fu J, Xu D, Liu Z, Shi M, Zhao P, Fu B, et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology. 2007;132:2328-39.
11. Ersvaer E, Liseth K, Skavland J, Gjertsen BT, Bruserud O. Intensive chemotherapy for acute myeloid leukemia differentially affects circulating TC1, TH1, TH17 and TREG cells. BMC Immunol. 2010;11:38.
12. Curti A, Pandolfi S, Valzasina B, Aluigi M, Isidori A, Ferri E, et al. Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25 T regulatory cells. Blood. 2007;109:2871-7.
13. Larmonier N, Marron M, Zeng Y, Cantrell J, Romanoski A, Sepassi M, et al. Tumor derived CD4-CD25- regulatory T cell suppression of dendritic cell function involves TGF beta and IL- 10. Cancer Immunol Immunother. 2007;56:48-59.
14. Clark RA, Huang SJ, Murphy GF, Mollet IG, Hijnen D, Muthukuru M, et al. Human squamous cell carcinomas evade the immune response by down-regulation of vascular E-selectin and recruitment of regulatory T cells. J Exp Med. 2008;205:2221-34.
15. Grauer OM, Sutmuller RP, van Maren W, Jacobs JF, Bennink E, Toonen LW, et al. Elimination of regulatory T cells is essential for an effective vaccination with tumor lysate-pulsed dendritic cells in a murine glioma model. Int J Cancer. 2008;122: 1794-802.
16. Ustun C, Miller JS, Munn DH, Weisdorf DJ, Blazar BR. Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation? Blood. 2011;118:5084-95.
17. Beyer M, Schultze JL. Regulatory T cells in cancer. Blood. 2006;108:804-11.
18. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10:942-9.
19. Griffiths RW, Elkord E, Gilham DE, Ramani V, Clarke N, Stern PL, et al. Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival. Cancer Immunol Immunother. 2007;56:1743-53.
20. Zhang S, Han Y, Wu J, Yu K, Bi L, Zhuang Y, et al. Elevated frequencies of CD4 CD25 CD127lo regulatory T cells is associated to poor prognosis in patients with acute myeloid leukemia. Int J Cancer. 2011;129:1373-81.
21. Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, et al. Metronomic cyclophosphamide regimen selectively depletes CD4 CD25 regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother. 2007;56:641-8.
22. Chu Y, Wang LX, Yang G, Ross HJ, Urba WJ, Prell R, et al. Efficacy of GM-CSF-producing tumor vaccine after docetaxel chemotherapy in mice bearing established Lewis lung carcinoma. J Immunother. 2006;29:367-80.